JP2024540304A5 - - Google Patents

Info

Publication number
JP2024540304A5
JP2024540304A5 JP2024526616A JP2024526616A JP2024540304A5 JP 2024540304 A5 JP2024540304 A5 JP 2024540304A5 JP 2024526616 A JP2024526616 A JP 2024526616A JP 2024526616 A JP2024526616 A JP 2024526616A JP 2024540304 A5 JP2024540304 A5 JP 2024540304A5
Authority
JP
Japan
Application number
JP2024526616A
Other languages
Japanese (ja)
Other versions
JP2024540304A (ja
JPWO2023079494A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/060616 external-priority patent/WO2023079494A1/en
Publication of JP2024540304A publication Critical patent/JP2024540304A/ja
Publication of JPWO2023079494A5 publication Critical patent/JPWO2023079494A5/ja
Publication of JP2024540304A5 publication Critical patent/JP2024540304A5/ja
Pending legal-status Critical Current

Links

JP2024526616A 2021-11-03 2022-11-03 抗cd38抗体による治療におけるコルチコステロイドの減少 Pending JP2024540304A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163275157P 2021-11-03 2021-11-03
US63/275,157 2021-11-03
US202163280791P 2021-11-18 2021-11-18
US63/280,791 2021-11-18
US202163288785P 2021-12-13 2021-12-13
US63/288,785 2021-12-13
US202263394726P 2022-08-03 2022-08-03
US63/394,726 2022-08-03
PCT/IB2022/060616 WO2023079494A1 (en) 2021-11-03 2022-11-03 Corticosteriod reduction in treatment with anti-cd38 antibodies

Publications (3)

Publication Number Publication Date
JP2024540304A JP2024540304A (ja) 2024-10-31
JPWO2023079494A5 JPWO2023079494A5 (https=) 2025-11-11
JP2024540304A5 true JP2024540304A5 (https=) 2025-11-11

Family

ID=84361138

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024526616A Pending JP2024540304A (ja) 2021-11-03 2022-11-03 抗cd38抗体による治療におけるコルチコステロイドの減少

Country Status (11)

Country Link
US (2) US20230136301A1 (https=)
EP (1) EP4426435A1 (https=)
JP (1) JP2024540304A (https=)
KR (1) KR20240099411A (https=)
AU (1) AU2022380155A1 (https=)
CA (1) CA3237175A1 (https=)
CL (1) CL2024001324A1 (https=)
IL (1) IL312514A (https=)
JO (1) JOP20240106A1 (https=)
MX (1) MX2024005406A (https=)
WO (1) WO2023079494A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025080911A1 (en) * 2023-10-12 2025-04-17 Janssen Biotech, Inc. Methods for treating multiple myeloma comprising an anti-cd38 antibody combined with bortezomib, lenalidomide and dexamethasone

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
ES2532399T3 (es) 2003-03-05 2015-03-26 Halozyme, Inc. Glicoproteína hialuronidasa soluble (sHASEGP), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden
DK2511297T3 (en) 2004-02-06 2015-06-15 Morphosys Ag Human anti-CD38 antibodies and their applications
EP2567976B1 (en) 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
EP2860192B1 (en) 2005-10-12 2017-09-27 MorphoSys AG Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
JP2011507519A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド pIX又はpVIIへの融合を介したヒトデノボpIXファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
EA033110B1 (ru) 2012-04-11 2019-08-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы
ES2774976T3 (es) 2013-04-29 2020-07-23 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
MX2017001079A (es) 2014-07-24 2017-09-12 Bluebird Bio Inc Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
SI3227339T1 (sl) 2014-12-05 2022-02-28 Memorial Sloan-Kettering Cancer Center Himerni antigenski receptorji, ki ciljajo na receptor, povezan z G-proteinom, in njihova uporaba
EA036379B1 (ru) 2014-12-12 2020-11-02 Блубёрд Био, Инк. Химерные антигенные рецепторы к bcma
MX389805B (es) * 2015-05-20 2025-03-11 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
US10072088B2 (en) 2015-08-17 2018-09-11 Janssen Pharmaceutica, Nv Anti-BCMA antibodies and uses thereof
DE102016211884A1 (de) 2016-06-30 2018-01-04 Zf Friedrichshafen Ag Getriebe für ein Kraftfahrzeug, sowie Antriebsstrang für ein Kraftfahrzeug
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗gprc5d抗體、結合gprc5d與cd3之雙特異性抗原結合分子及其用途
EP4282877A3 (en) 2016-08-10 2024-02-21 Legend Biotech Ireland Limited Chimeric antigen receptors targeting bcma and methods of use thereof
MA53122A (fr) 2018-07-13 2021-05-19 Genmab As Variants d'anticorps cd38 et leurs utilisations
WO2020081881A2 (en) * 2018-10-17 2020-04-23 Janssen Biotech, Inc. Method of providing subcutaneous administration of anti-cd38 antibodies
JP7303314B2 (ja) 2019-01-18 2023-07-04 ヤンセン バイオテツク,インコーポレーテツド Gprc5dキメラ抗原受容体及びそれを発現する細胞
US20200308297A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses

Similar Documents

Publication Publication Date Title
CL2025003826A1 (es) Método y sistema para el análisis de datos de monitorización de redes de distribución eléctrica
BR102022025291A2 (https=)
JP2024540304A5 (https=)
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY13144U (https=)
BY13143U (https=)
CN307045253S (https=)
CN307045141S (https=)
BY13141U (https=)
BY13140U (https=)
CN307044525S (https=)
CN307044523S (https=)